Leslie Stolz

General Counsel at VERVE THERAPEUTICS, INC.

52 year

Health Technology

Consumer Services

Profile

Leslie Stolz is currently working as the Senior Vice President-Regulatory Affairs at Verve Therapeutics, Inc. Prior to this, Leslie worked as the Vice President-Regulatory Strategy at Syntimmune, Inc. Leslie holds a doctorate degree from Duke University and an undergraduate degree from Villanova University.

Leslie Stolz active positions

Companies	Position	Start
VERVE THERAPEUTICS, INC.	General Counsel	2019-05-31

All active positions of Leslie Stolz

Former positions of Leslie Stolz

Companies	Position	End
Syntimmune, Inc. Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA.	Corporate Officer/Principal	2017-12-31

See the detail of Leslie Stolz's experience

Training of Leslie Stolz

Duke University	Doctorate Degree
Villanova University	Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Leslie Stolz's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
VERVE THERAPEUTICS, INC.	Health Technology

Private companies	1
Syntimmune, Inc. Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA.	Health Technology